Please use this identifier to cite or link to this item:
https://repository.unad.edu.co/handle/10596/65269Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.advisor | Lozano, Esmeralda | |
| dc.coverage.spatial | ceres_-_la_plata | |
| dc.creator | Cardona Gómez, Karen Sofía | |
| dc.creator | Fetecua Osorio, Martha Patricia | |
| dc.creator | Narváez Madrigal, Karen Yuliana | |
| dc.creator | Lizcano Yara, Jhan Carlos | |
| dc.creator | Trujillo Cerquera, Edna Alejandra | |
| dc.date.accessioned | 2024-12-16T15:37:20Z | - |
| dc.date.available | 2024-12-16T15:37:20Z | - |
| dc.date.created | 2024-12-14 | |
| dc.identifier.uri | https://repository.unad.edu.co/handle/10596/65269 | - |
| dc.description | Ninguno | |
| dc.description.abstract | El presente trabajo tiene como finalidad proponer el diseño y la propuesta de integración de un sistema de farmacovigilancia basado en inteligencia artificial en una institución de salud de baja complejidad. Se centra en optimizar la detección y prevención de eventos adversos relacionados con medicamentos biológicos y biosimilares. La investigación se trata acerca de la importancia de la trazabilidad y la formación del personal médico para garantizar la seguridad del paciente. Mediante una revisión cualitativa, se recopilaron y analizaron datos de fuentes confiables y diversas bases académicas internacionales. Para ello, se emplearon palabras clave relacionadas con "farmacovigilancia", "inteligencia artificial" e "IPS de baja complejidad en Colombia”, priorizando estudios recientes y pertinentes al contexto de los medicamentos biológicos y biosimilares. Se concluye que la implementación de la inteligencia artificial en sistemas de farmacovigilancia representa una oportunidad significativa para optimizar la precisión en la identificación y gestión de eventos adversos relacionados con el uso de medicamentos. Además, permite mitigar riesgos asociados al consumo inadecuado o inseguro de estos productos. | |
| dc.format | ||
| dc.title | Estudio sobre sistemas de farmacovigilancia asistidos por inteligencia artificial en una IPS de baja complejidad que promueva el uso de medicamentos biológicos y biosimilares | |
| dc.type | Diplomado de profundización para grado | |
| dc.subject.keywords | Farmacovigilancia | |
| dc.subject.keywords | Inteligencia artificial (IA) | |
| dc.subject.keywords | Medicamentos biológicos | |
| dc.subject.keywords | Biosimilares | |
| dc.subject.keywords | IPS | |
| dc.subject.keywords | Seguridad del paciente | |
| dc.subject.keywords | Eventos adversos | |
| dc.subject.keywords | Trazabilidad. | |
| dc.description.abstractenglish | The purpose of this work is to propose the design and integration proposal of a pharmacovigilance system based on artificial intelligence. It focuses on optimizing the detection and prevention of adverse events related to biological and biosimilar drugs. The research deals with the importanceof traceability and the training of the personal physician to ensure patient safety. Through a descriptive and correlational approach, it is intended to analyze the effectiveness of the system, addressing challenges such as lack of training and high costs. It is concluded that AI offers opportunities to improve accuracy and reduce risks, by helping to use and educate the patient safely for the consumption of medications. Through a qualitative review, data were collected and analyzed from reliable sources and various international academic databases. Keywords related to "pharmacovigilance," "artificial intelligence," and "low-complexity healthcare institutions in Colombia" were used, prioritizing recent studies relevant to the context of biological and biosimilar medications. It is concluded that the implementation of artificial intelligence in pharmacovigilance systems represents a significant opportunity to optimize accuracy in the identification and management of adverse events related to medication use. Additionally, it enables the mitigation of risks associated with improper or unsafe consumption of these products. | |
| dc.subject.category | Farmacovigilancia | |
| Appears in Collections: | Diplomado de Farmacovigilancia | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| jcliscanoy2.pdf | 568.69 kB | Adobe PDF |  View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.